• Reata Pharma Drug Wins First FDA Nod in Ultra-Rare Neuromuscular Disorder

    24 days ago - By MedCity News

    Skyclarys, a Reata Pharmaceuticals drug, is now approved for treating the rare neuromuscular disorder Friedreich's ataxia. The decision makes the capsule the first therapy for a disease that's rarer than either Duchenne muscular dystrophy or spinal muscular atrophy.
    Read more ...

     

  • STAT+: FDA approves Reata's treatment for rare neurological disease

    STAT+: FDA approves Reata's treatment for rare neurological disease

    25 days ago - By STAT

    The Food and Drug Administration on Tuesday approved the first drug to treat Friedreich's Ataxia, a rare, neurological disease.
    The new drug, called Skyclarys, is made by Reata Pharmaceuticals. Continue to STAT+ to read the full story...
    Read more ...